The CM from cixutumumab-treated cancer cells failed to increase CXCL8 transcripts in Wi38 cells with an shRNA-mediated loss of IGF-2R expression and also in cells that had been incubated with neutralizing antibody blocking IGF-2R (Fig. 7c and Supplementary Fig. 18). Here, CXCL8 is linked to cancer.